Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-MeO-DMT for Anxiety and Depression in Alzheimer's Disease/MCI
NCT06812221Phase 2Completed
- Sponsor
- Biomind Labs
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), anxiety disorder and 1 more comparing 5-MeO-DMT with Placebo (2 arms). Primary endpoints: Phonological Verbal Fluency Test at Week 5, Paced Auditory Serial Addition Test at Week 5 and 4 more. Started Dec 2024; status: completed.
02
Drugs
5-MeO-DMT
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06812221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812221.